The interaction of intense synchrotron radiation with molecular crystals frequently modifies the crystal structure by breaking bonds, producing fragments and, hence, inducing disorder. Here, a second-rank tensor of radiation-induced lattice strain is proposed to characterize the structural susceptibility to radiation. Quantitative estimates are derived using a linear response approximation from experimental data collected on three materials Hg(NO3)2(PPh3)2, Hg(CN)2(PPh3)2 and BiPh3 [PPh3 = triphenylphosphine, P(C6H5)3; Ph = phenyl, C6H5], and are compared with the corresponding thermal expansivities. The associated eigenvalues and eigenvectors show that the two tensors are not the same and therefore probe truly different structural responses. The tensor of radiative expansion serves as a measure of the susceptibility of crystal structures to radiation damage.

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

On-Demand Webinar > Watch Now!>>SPONSORED BY: TripwireResearch shows that over a third of organizations are not prepared for breaches while the average cost per breach in 2009 was $6.7 millio...

Half-facepiece reusable elastomeric respirators are an effective and viable option for protecting health care workers from exposure to airborne transmissible contaminants or infectious agents — for example, influenza virus — during day-to-day work or with a sudden or rapid influx of patients, such as during a public health emergency, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The White House Office of Science and Technology Policy (OSTP) this week requested that the National Academies of Sciences, Engineering, and Medicine rapidly examine the information and data needed to help determine the origins of the novel coronavirus that is causing a global outbreak of respiratory illness.

WASHINGTON — In response to the COVID-19 outbreak, the White House Office of Science and Technology Policy has asked the National Academies of Sciences, Engineering, and Medicine to establish a Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats.

The National Academies of Sciences, Engineering, and Medicine announced today that Harvey Fineberg, former president of the Institute of Medicine (now the National Academy of Medicine) and current president of the Gordon and Betty Moore Foundation, will serve as the chair of the Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats.

Formed earlier this month, the National Academies’ Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats was assembled at the request of the White House Office of Science and Technology Policy and the Office of the Assistant Secretary for Preparedness and Response in response to the COVID-19 outbreak.

As the COVID-19 pandemic grips the nation and the world, policymakers and the public are counting on science, engineering, and medicine to discover how the virus infects humans, slow its spread, treat those infected, and provide solutions that lay the groundwork for recovery.

The recently formed National Academies Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats, assembled at the request of the White House Office of Science and Technology Policy and the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response in response to the COVID-19 outbreak, has been providing rapid expert consultations on several topics, such as social distancing and severe illness in young adults.

The recently formed National Academies Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats, assembled at the request of the White House Office of Science and Technology Policy (OSTP) and the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response in response to the COVID-19 outbreak, has been providing rapid expert consultations on several topics, such as social distancing and severe illness in young adults.

A new rapid expert consultation from a standing committee of the National Academies of Sciences, Engineering, and Medicine responds to questions from the White House Office of Science and Technology Policy (OSTP) regarding survival of the COVID-19 virus in relation to temperature and humidity and potential for seasonal reduction and resurgence of cases.

A new rapid expert consultation from a standing committee of the National Academies of Sciences, Engineering, and Medicine.

A new rapid expert consultation from a standing committee of the National Academies of Sciences, Engineering, and Medicine responds to questions from the White House Office of Science and Technology Policy (OSTP) regarding the effectiveness of homemade fabric masks to protect others from the viral spread of COVID-19 from potentially contagious asymptomatic or presymptomatic individuals.

Anthony Fauci and other panelists explored the status of the pandemic, research underway, and the key role of vaccines in bringing the pandemic to an end.

National Academy of Medicine President Victor J. Dzau will provide remarks on behalf of the Global Preparedness Monitoring Board during a virtual event on May 4 to launch an online pledging effort, the Coronavirus Global Response.

Research and funding priorities tend to shift from one disaster to the next, which has resulted in a sparse evidence base and hampers the nation’s ability to respond to public health emergencies in the most effective way, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new rapid expert consultation from a standing committee of the National Academies of Sciences, Engineering, and Medicine outlines considerations for clinical staffing needs during the implementation of Crisis Standards of Care (CSC), including adjusting staff responsibilities, providing “hazard pay” to staff, ensuring adequate time off, offering child care and other benefits, and leveraging health care coalitions to ensure appropriate transfer of patients between hospitals.

In a matter of months, the coronavirus pandemic has triggered a global health, economic, and societal crisis of staggering proportions.

For his role as a leader of federal research and policy on infectious diseases and, in particular, for his deft, scientifically grounded leadership in shaping an effective response to the COVID-19 pandemic, the National Academy of Medicine today announced Anthony S. Fauci is the recipient of the 2020 Gustav O. Lienhard Award for Advancement of Health Care.

National Academy of Engineering (NAE) President John Anderson sat down to talk about some of the engineering challenges posed by the pandemic and how engineers — and the NAE in particular — are working to meet them.

As many nations around the world have struggled with high rates of infections and deaths from COVID-19, Taiwan has kept the number of deaths from the disease to less than 10 — by drawing upon its previous experience with SARS, said chemical engineer Pam Cheng, speaking at last week’s annual meeting of the National Academy of Engineering.

A new rapid expert consultation from a standing committee of the National Academies of Sciences, Engineering, and Medicine examines four topics related to the use and interpretation of COVID-19 diagnostic tests.

A new rapid expert consultation from the National Academies of Sciences, Engineering, and Medicine examines methods to better track and evaluate deaths and mental health consequences among health care workers (HCWs) due to COVID-19.

Despite a scarce supply, a substantial amount of COVID-19 monoclonal antibody (mAb) treatment courses remain unused, says a new rapid expert consultation from the National Academies of Sciences, Engineering, and Medicine.

A new rapid expert consultation from the National Academies of Sciences, Engineering, and Medicine identifies strategies for emergency planners and decision-makers to consider as they update their disaster plans for evacuation, sheltering, and mass care amid COVID-19.

Young and middle-aged adults (25-64 years old) in the U.S. have been dying at higher rates since 2010, according to a new report from the National Academies of Sciences, Engineering, and Medicine.

The National Academy of Medicine (NAM) has established an international committee (IC) in coordination with the U.S. Department of Health and Human Services’ Office of Global Affairs (OGA) to inform and facilitate efforts to advance global influenza pandemic preparedness.

The COVID-19 pandemic has presented a relatively rare situation in which the entire globe is grappling with the same crisis at the same time, albeit with widely varying approaches, resource levels, and political structures.

How can engineers help the nation mitigate and adapt to climate change? In advance of the National Academy of Engineering’s annual meeting — which will explore that question — NAE President John L. Anderson sat down to discuss the contributions engineering can make.

A University of Oklahoma study demonstrates for the first time that remote sensing data from weather surveillance radar and on-the-ground data from the eBird citizen science database both yield robust indices of migration timing, also known as migration phenology. These indices can now be used to address the critical gap in our knowledge regarding the cues that migrants use for fine tuning their migration timing in response to climate.

read more

Manufacturers can improve workplace safety and minimize unplanned downtime if they know how sudden equipment failures occur and what to do about them. 

ISHN recently exchanged an email Q&A with Amanda Alexander, global product manager for Emerson’s Location Awareness System.

A step into a prestigious new space

Cash for Gold Mailer, a leading provider of secure and convenient gold selling services, is excited to announce a limited-time offer of a 10% bonus on all gold transactions.

New Emergency Locksmith Services Provide Immediate Assistance for Lockouts, Broken Keys, and Security Issues Across Bowling Green, KY

List now includes household protected products, safety protective products and preventive cleaning products

DRTV Agency and Per Inquiry TV Agency InfoWorx Direct rocked the 10th Annual SIAA Awards this year winning six key awards. InfoWorx is a pioneer in new opportunities for Direct Response TV, Per Inquiry TV, DR Radio, and Pay Per Call Mobile.

New website offering 80% lower receivers, complete uppers, barrels, jigs, or other firearm parts to create customized AR-15, AR-10, AR-9, or .300 Blackouts.

Rapid Response for inclement winter weather

How Fast Guard Service assist property management companies around the clock.

Considering the major societal disruptions brought on by government mandates responding to the COVID19 pandemic, all communities owe their residents an objective review of the mandates imposed.

A team of Marine Corps Veterans launch The Salty Seabag, customizing survival gear for individuals, families, and disaster response organizations with cutting-edge tech.

Automotive Defense Specialists is proud to announce a strong response to its recent information posts on legal issues for smog shops and auto repair technicians. The posts explain 'hot button' issues impacting California's hard-working smog and auto.

A colleague who works in a field that uses a lot of survey research asks: Can you recommend papers about detecting bad survey responses? We have some such methods where I work, but I’m curious what the Census Bureau and … Continue reading →

DALLAS, January 3, 2023 —While playing in the Buffalo Bills - Cincinnati Bengals game on Monday Night Football on January 2, Bills player Damar Hamlin suffered a cardiac arrest after a hit and was administered CPR on the field before being transferred to...

For many people, it’s a ray of hope rooted in research. Recent research is presenting a new way of thinking about suicide prevention, and both experts and patients believe it’s already saving lives.

Most know the word “cancer” as a negative thing.  As a disease characterized by the body’s cells growing uncontrollably, cancer rema

Most know the word “cancer” as a negative thing.  As a disease characterized by the body’s cells growing uncontrollably, cancer rema